glp 1 and high triglycerides GLP-1 Receptor Agonists for the Reduction of Atherosclerotic Cardiovascular Risk in Patients With Type 2 Diabetes Frontiers | Mechanisms of action
Description
The injectable requires refrigeration
In some cases, plaintiffs also allege defects in the drugs design or labeling
Both glucagon-like peptide-1 receptor agonists (GLP-1RAs) and sodium-glucose cotransporter-2 inhibitors (SGLT2is) have individually been shown to reduce cardiovascular and kidney outcomes in patients with T2DM, with a low hypoglycemia risk [3, 4]
What patients see today as cutting-edge therapy is in fact the culmination of decades of rigorous, peer-reviewed scientific inquiry and drug development
The content is not intended to encourage application, diagnosis, or self-treatment of unlicensed individuals, and should not be used as a substitute for the clinical judgment of a qualified healthcare provider.
For people with Type 2 diabetes and obesity, weight loss often improves blood sugar levels and overall health
